Stay updated on Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial
Sign up to get notified when there's something new on the Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial page.

Latest updates to the Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial page
- Check4 days agoChange DetectedScreenshots show no visible additions or deletions; page content appears unchanged between versions.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedA new site revision v3.5.0 has been added and the older revision v3.4.3 has been removed.SummaryDifference0.1%

- Check25 days agoChange Detected- Page template revision updated from v3.4.2 to v3.4.3. This is a metadata/update that does not affect study details or how users interact with the page.SummaryDifference0.1%

- Check54 days agoChange DetectedAdded Revision: v3.4.2. Removed the prior government funding status notice associated with v3.4.1.SummaryDifference0.4%

- Check61 days agoChange DetectedA new system notice about government funding has been added. The site revision updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check68 days agoChange DetectedAdded a glossary toggle and updated metadata labels to show 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and a new footer 'Revision: v3.4.0', while the previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and version 'Revision: v3.3.4' were replaced.SummaryDifference0.2%

Stay in the know with updates to Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial page.